NK Cell Therapy Breakthrough Uses Supplements to Fight Cancer's Lactate Defense

This groundbreaking study reveals how tumors defend themselves by producing lactate that weakens the immune system's natural killer (NK) cells, and identifies a promising supplement-based solution to restore their cancer-fighting power.

Researchers investigated how tumor-derived lactate impairs NK cells through lysine lactylation (Kla), a chemical modification that damages cellular function. They found that increased lactylation levels in NK cells led to disrupted energy metabolism, fragmented mitochondria, and severely reduced ability to kill cancer cells.

The team tested a combination of two supplements: nicotinamide riboside (a precursor to NAD+, the cellular energy molecule) and honokiol (a compound that activates SIRT3, a longevity-associated protein). This combination successfully reduced lactylation levels and restored NK cell cytotoxicity both in laboratory studies and living models.

The mechanism involves preventing lactylation of ROCK1 protein, which normally triggers mitochondrial fragmentation through the ROCK1-DRP1 signaling pathway. By blocking this process, the supplements maintained healthy mitochondrial structure and function in NK cells even in lactate-rich tumor environments.

These findings could revolutionize NK cell-based immunotherapies by making them more effective against solid tumors, which typically create hostile, lactate-rich environments. The supplement approach offers a potentially safer and more accessible way to enhance immune function compared to genetic modifications. However, human clinical trials are needed to confirm safety and effectiveness.